| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3667 | Nmda298-1 | Novel inhibitor of glioma-associated oncogene homologue 1 (Gli1) mediated transcription |
|
| DCC3668 | Nmdi14 | Novel Inhibitor of Nonsense-Mediated RNA Decay, Suppressing Nonsense p53 Mutations |
|
| DCC3669 | N-me-aminopyrimidinone 9 | Potent and state-dependent Nav1.7 antagonist |
|
| DCC3670 | Nmi801 | Novel Mdm2 inhibitor, acting as a negative regulator of p53, reducing viability in cell culture and suppressing tumor growth |
|
| DCC3671 | nmk-td-100 | Novel Microtubule Modulator, Blocking Mitosis and Inducing Apoptosis in HeLa Cells by Binding to Tubulin |
|
| DCC3672 | nms859 | Covalent and allosteric inhibitor of the ATPase VCP/p97, inducing cancer cell death |
|
| DCC3673 | Nms-p715 Analog | Novel selective and orally bioavailable MPS1 inhibitor |
|
| DCC3674 | Nms-p953 | Novel JAK2 inhibitor, displaying significant tumor growth inhibition in SET-2 xenograft tumor model, with a mechanism of action confirmed in vivo by typical modulation of known biomarkers, and with a favorable pharmacokinetic and safety profile |
|
| DCC3675 | Nn9056 | Novel Potent and Highly Selective, Long-Acting, Peptide-Based Cholecystokinin 1 Receptor (CCK-1R) Agonist |
|
| DCC3676 | N-n-butyl Haloperidol Iodide | Novel inhibitor of autophagy, protecting cardiomyocytes against hypoxia/reoxygenation injury |
|
| DCC3677 | Nnc-38-1049 | Novel selective histamine H3 antagonist |
|
| DCC3678 | Nn-dnj | Iminosugar, binding to the active site of lysosomal beta-glucosidase and stabilizing the proper folding for the catalytic form, acting as a chemical chaperone that facilitate transport and maturation of acid beta-Glu |
|
| DCC3679 | Nnmt Inhibitor Ns1 | Novel potent alkynyl bisubstrate inhibitor of nicotinamide N-methyltransferase (NNMT) |
|
| DCC3680 | nnrti F2 | Novel non-nucleoside reverse transcriptase inhibitor (NNRTI) |
|
| DCC3681 | Nocardicin A | Moderate antibiotic agent against a broad spectrum of gram-negative bacteria |
|
| DCC3682 | Nocardicin G | The universal precursor of the nocardicins |
|
| DCC3683 | Nocathiacin I | Natural Inhibitor of an Oncogenic RNA, targeting RNA folds in the nuclease processing site in the oncogenic, noncoding microRNA-18a, selectively inhibiting nuclease processing in vitro and in prostate cancer cells and triggering apoptosis |
|
| DCC3684 | nocazine C | Nocazine family member |
|
| DCC3685 | nocazine E | Marine natural nocazine family member; Standard used in nocazine biosynthetic parthway studies |
|
| DCC3686 | Nociceptin | Neuropeptide, acting as a endogenous ligand for the nociceptin receptor (NOP, ORL-1) |
|
| DCC3687 | N-oleoylethanolamine | PPARalpha agonist and EC 3.5.1.23 (ceramidase) inhibitor |
|
| DCC3688 | Nomegestrol | Steroidal progestin |
|
| DCC3689 | Nomegestrol Acetate | Neutral, nonandrogenic, progesterone-like profile progestin |
|
| DCC3690 | Nonoxynol-9 | Novel human epidermal growth factor receptor-2 (HER2) inhibitor; Spermatocide |
|
| DCC3691 | Nord-1 | Novel red-light-controllable nitric oxide (NO) releaser |
|
| DCC3692 | Nor-fauc-365 | FAUC-365 analog |
|
| DCC3693 | Norgestomet | Steroidal progestin used in veterinary medicine to control estrus and ovulation in cattle |
|
| DCC3694 | Noricumazole A | Secondary metabolite from the myxobacterium Sorangium cellulosum, acting as a potent HCV inhibitor, Ebola virus (EBOV) entry inhibitor, and a potassium channel inhibitor |
|
| DCC3695 | No-rosa5 | Controllable nitric oxide (NO) donor, releasing NO triggered by photoinduced electron transfer (PeT) |
|
| DCC3696 | Noscapine | Natueal sigma receptor agonist, attenuating cytokine release associated with SARS-CoV-2, also being used as anti-malarial, anti-stroke and cough-suppressant |
|
